NO20042958L - Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus - Google Patents

Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus

Info

Publication number
NO20042958L
NO20042958L NO20042958A NO20042958A NO20042958L NO 20042958 L NO20042958 L NO 20042958L NO 20042958 A NO20042958 A NO 20042958A NO 20042958 A NO20042958 A NO 20042958A NO 20042958 L NO20042958 L NO 20042958L
Authority
NO
Norway
Prior art keywords
poxviruses
methods
containing poxviruses
stable compositions
preparing stable
Prior art date
Application number
NO20042958A
Other languages
English (en)
Inventor
Karl Heller
Ingmar Rathe
Paul Howley
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042958(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NO20042958L publication Critical patent/NO20042958L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20042958A 2001-12-10 2004-07-09 Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus NO20042958L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101831 2001-12-10
PCT/EP2002/013434 WO2003053463A2 (en) 2001-12-10 2002-11-28 Poxvirus-containing compositions and process for their preparation

Publications (1)

Publication Number Publication Date
NO20042958L true NO20042958L (no) 2004-07-09

Family

ID=8160885

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042958A NO20042958L (no) 2001-12-10 2004-07-09 Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus

Country Status (22)

Country Link
US (1) US7094412B2 (no)
EP (1) EP1418942B1 (no)
JP (1) JP4439263B2 (no)
KR (1) KR20040074067A (no)
CN (1) CN1296096C (no)
AT (1) ATE300954T1 (no)
AU (1) AU2002361962A1 (no)
BR (1) BR0214822A (no)
CA (1) CA2467365C (no)
DE (1) DE60205388T2 (no)
DK (1) DK1418942T3 (no)
EA (1) EA006880B1 (no)
ES (1) ES2247414T3 (no)
HK (1) HK1071295A1 (no)
HU (1) HUP0402179A3 (no)
IL (2) IL161590A0 (no)
MX (1) MXPA04005577A (no)
NO (1) NO20042958L (no)
NZ (1) NZ533302A (no)
PL (1) PL213326B1 (no)
UA (1) UA78738C2 (no)
WO (1) WO2003053463A2 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
NZ538575A (en) 2002-09-05 2007-03-30 Bavarian Nordic As Method for the amplification of a virus wherein primary avian cells are cultivated in a serum-free medium comprising growth factors and attachment factors
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
CN104984352A (zh) * 2005-11-21 2015-10-21 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
WO2008138533A1 (en) 2007-05-14 2008-11-20 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8617576B2 (en) * 2007-05-18 2013-12-31 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
KR20120093941A (ko) 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
AU2011254315B2 (en) 2010-05-21 2015-05-14 Zoetis Services Llc Parapoxvirus vectors containing rabies virus antigen
EP2595652A1 (en) 2010-07-20 2013-05-29 Ah Usa 42 Llc Parapoxvirus vectors
NZ603620A (en) 2010-07-20 2015-01-30 Bavarian Nordic As Method for harvesting expression products
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
EP3169341B1 (en) 2014-07-16 2019-06-05 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
US10517943B2 (en) 2014-12-01 2019-12-31 Transgene S.A. Stable liquid vaccinia virus formulations
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
ES2905478T3 (es) 2016-12-28 2022-04-08 Transgene Sa Virus oncolíticos y moléculas terapéuticas
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3638302B1 (en) 2017-06-15 2024-03-13 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
EP3875119A4 (en) 2018-10-30 2022-08-31 The University of Tokyo ONCOLYTIC VIRUS FOR THE TREATMENT OF CANCER
SG11202106898VA (en) 2018-12-28 2021-07-29 Transgene Sa M2-defective poxvirus
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
MX2022011071A (es) 2020-03-12 2022-09-23 Bavarian Nordic As Composiciones que mejoran la estabilidad del poxvirus.
US12029787B2 (en) 2020-07-01 2024-07-09 University Of Connecticut Method for generating recombinant poxviruses
CA3189238A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003239A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024003238A1 (en) 2022-06-29 2024-01-04 Bavarian Nordic A/S Epstein-barr-virus vaccine
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
WO2024149832A1 (en) 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (no)
US4380582A (en) * 1965-07-09 1983-04-19 The United States Of America As Represented By The Secretary Of The Army Preparation of dry variola virus
FR7773M (no) * 1968-06-14 1970-03-23
US3577526A (en) * 1969-06-13 1971-05-04 Merieux Inst Stabilized smallpox vaccine
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
WO1995010601A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
EP0951555A2 (en) * 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors

Also Published As

Publication number Publication date
CA2467365C (en) 2012-11-20
DK1418942T3 (da) 2005-11-28
EP1418942A2 (en) 2004-05-19
AU2002361962A1 (en) 2003-07-09
IL161590A (en) 2009-06-15
PL369954A1 (en) 2005-05-02
EP1418942B1 (en) 2005-08-03
CN1296096C (zh) 2007-01-24
PL213326B1 (pl) 2013-02-28
KR20040074067A (ko) 2004-08-21
WO2003053463A2 (en) 2003-07-03
ES2247414T3 (es) 2006-03-01
CA2467365A1 (en) 2003-07-03
BR0214822A (pt) 2004-12-14
JP4439263B2 (ja) 2010-03-24
WO2003053463A3 (en) 2004-03-04
IL161590A0 (en) 2004-09-27
EA006880B1 (ru) 2006-04-28
DE60205388T2 (de) 2006-03-30
JP2005513109A (ja) 2005-05-12
DE60205388D1 (de) 2005-09-08
UA78738C2 (en) 2007-04-25
HUP0402179A3 (en) 2012-09-28
NZ533302A (en) 2005-11-25
US20050019349A1 (en) 2005-01-27
EA200400796A1 (ru) 2004-12-30
HUP0402179A2 (hu) 2005-01-28
US7094412B2 (en) 2006-08-22
MXPA04005577A (es) 2005-04-19
ATE300954T1 (de) 2005-08-15
CN1602205A (zh) 2005-03-30
HK1071295A1 (en) 2005-07-15

Similar Documents

Publication Publication Date Title
NO20042958L (no) Formuleringer som inneholder poxvirus og fremgangsmate til fremstilling av stabile sammensetninger som inneholder poxvirus
ATE397936T1 (de) Therapeutische verfahren unter verwendung von pflanzlichen zusammensetzungen
BR0315767A (pt) Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
NO20072714L (no) Forbedret baereformulering
UY27854A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
GB0119011D0 (en) Treatment of nail infections
NZ596367A (en) Lyophilized therapeutic peptibody formulations
AR030088A1 (es) Nueva composicion de minoxidilo
EP2275121A3 (en) Protein-based streptococcus pneumoniae vaccines
GT200100126A (es) Preparaciones de retardo de antibioticos de quinolona y procedimiento para su fabricacion.
EP4085131A4 (en) AGAINST THE SARS-CORONAVIRUS 2 IMMUNOGENE COMPOSITIONS, METHOD FOR THEIR PRODUCTION AND THEIR USE
WO2002087494A3 (en) Novel vaccine
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
BRPI0208411B8 (pt) composto, composição farmacêutica tópica para tratamento profilático ou terapêutico de doenças sexualmente transmitidas em um paciente humano, e, uso de um composto
DE60140997D1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
WO2003057153A3 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
ITMI20031640A1 (it) Base per gel bioadesivi.
WO2022108692A3 (en) Solid dispersion genistein compositions and methods of making and using the same
NZ528544A (en) Formulations comprising entrapped active ingredients and uses thereof
AU2001256384A1 (en) Cosmetic or dermatological cream composition, the preparation and the use thereof
CN105326762A (zh) 一种芦荟保湿护手霜
BRPI0103733A8 (pt) Método de encapsulação de ingredientes alimentícios e composição alimentícia
PT1363603E (pt) Processo para tornar hidrossoluvel um anti-septico pouco soluvel em agua
TW200626127A (en) Dried material and method for producing the same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application